ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care in its leading scientific journal, Annals of Oncology today.
Dec 15, 2017
0
6
One out of every five new cancer patients is diagnosed with a rare cancer, yet the clinical evidence needed to effectively treat these rare cancer patients is scarce. Indeed, conventional cancer clinical trial methodologies ...
Oct 28, 2014
0
0
A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer, especially in poorer countries. The results were presented at the ...
Apr 30, 2019
0
0
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic ...
Feb 10, 2014
0
0
The DATECAN initiative, Definition for the Assessment of Time-to-event Endpoints in CANcer trials, has published Guidelines for time-to-event end point definitions in breast cancer trials in a recent issue of the Annals of ...
May 19, 2015
0
2
Since its introduction in 2015, a prediction tool developed by the European Society of Medical Oncology (ESMO) has been providing support worldwide in the assessment of the clinical benefits of new cancer therapies. However, ...
Jun 20, 2023
0
15
